Modernizing Pharmaceutical Manufacturing: from Batch to Continuous Production
- First Online:
- Cite this article as:
- Lee, S.L., O’Connor, T.F., Yang, X. et al. J Pharm Innov (2015) 10: 191. doi:10.1007/s12247-015-9215-8
- 2.7k Downloads
The Food and Drug Administration (FDA) regulates pharmaceutical drug products to ensure a continuous supply of high-quality drugs in the USA. Continuous processing has a great deal of potential to address issues of agility, flexibility, cost, and robustness in the development of pharmaceutical manufacturing processes. Over the past decade, there have been significant advancements in science and engineering to support the implementation of continuous pharmaceutical manufacturing. These investments along with the adoption of the quality-by-design (QbD) paradigm for pharmaceutical development and the advancement of process analytical technology (PAT) for designing, analyzing, and controlling manufacturing have progressed the scientific and regulatory readiness for continuous manufacturing. The FDA supports the implementation of continuous manufacturing using science- and risk-based approaches.